AOD-9604 and Fat Metabolism Research: Lipolysis, Adipogenesis and Metabolic Biology (UK 2026)

AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment of the C-terminal region of growth hormone — specifically the 176–191 amino acid fragment of GH, with a tyrosine substitution at the N-terminal position (Tyr-hGH177-191). It was developed by Monash University researchers who identified that the fat metabolism effects of GH are encoded in this specific C-terminal region, while the growth-promoting and diabetogenic effects reside in other regions of the GH molecule. AOD-9604 therefore represents an attempt to isolate GH’s lipolytic activity as a research tool — a metabolically selective GH fragment for fat biology research.

Growth Hormone and Fat Metabolism: The Background

Growth hormone has profound effects on body composition — its anabolic effects on muscle protein synthesis and its lipolytic effects on adipose tissue collectively drive the lean, muscular phenotype associated with high GH states. GH deficiency in adults produces a characteristic body composition change: increased visceral adiposity, reduced lean mass — effects reversed by GH replacement therapy.

GH’s lipolytic effects are mediated through several mechanisms: direct activation of hormone-sensitive lipase (HSL) in adipocytes (through cAMP-mediated pathways), anti-insulin effects that reduce adipocyte glucose uptake (limiting triglyceride re-esterification), and ATGL (adipose triglyceride lipase) upregulation. The net effect is enhanced lipolysis — mobilisation of stored triglycerides as free fatty acids into circulation — and reduced adipogenesis (differentiation of pre-adipocytes into mature fat cells).

However, full-length GH also has significant downsides for isolated fat metabolism research: it stimulates insulin resistance, activates IGF-1R signalling producing anabolic effects on multiple tissues, and has complex pleiotropic actions that confound clean study of fat metabolism specifically. AOD-9604 was developed to provide the lipolytic activity without these confounding systemic GH effects.

AOD-9604 Mechanism: GH-Fragment Lipolysis

AOD-9604 does not bind the classical GH receptor (GHR) — the receptor through which full-length GH drives IGF-1 production, growth, and insulin resistance. This GHR bypass means AOD-9604 does not elevate IGF-1 or produce insulin resistance — the primary safety concerns associated with full-length GH administration.

The mechanism of AOD-9604’s lipolytic activity is less completely characterised than that of full-length GH. The C-terminal fragment appears to interact with a membrane receptor or lipid-binding pathway in adipocytes distinct from GHR — potentially through direct activation of β-adrenergic-like cAMP cascades in adipocytes, or through adipocyte-specific receptor systems yet to be fully characterised. Regardless of the precise upstream mechanism, the documented downstream effects include:

Enhanced lipolysis — increased fatty acid release from adipocyte triglyceride stores, measured by glycerol release (the backbone of triglycerides released during lipolysis) and non-esterified fatty acid (NEFA) elevation in plasma.

Reduced adipogenesis — pre-adipocyte differentiation into mature adipocytes is suppressed by AOD-9604 treatment in culture models, reducing the expansion of the adipose tissue compartment.

In obese animal models (diet-induced obesity, ob/ob mice), AOD-9604 administration produces significant reductions in body fat mass without the growth-promoting effects of full-length GH — demonstrating in vivo selectivity for the fat compartment.

Clinical Evidence

AOD-9604 was progressed through Phase 1 and Phase 2 clinical trials by Metabolic Pharmaceuticals (a Monash University spin-out) for the treatment of obesity. Phase 1 trials in healthy volunteers confirmed the absence of GHR-mediated effects (no IGF-1 elevation, no glucose metabolism disruption) and good tolerability. Phase 2 trials in overweight adults showed modest but statistically significant weight loss versus placebo in some cohorts at certain dose levels.

The clinical programme was not advanced to Phase 3 — the weight loss effects, while real, were modest in magnitude relative to the competitive landscape of obesity pharmacology, and the regulatory investment required for Phase 3 approval was not pursued. AOD-9604 was subsequently awarded “Generally Recognised as Safe” (GRAS) status by the US FDA in 2014 for use as a food ingredient — an unusual regulatory pathway that reflects its safety profile rather than efficacy approval.

The GRAS status is specifically for the food ingredient application. AOD-9604 in research peptide form remains a research compound supplied under RUO designation.

Osteoarthritis Research: An Unexpected Application

Beyond fat metabolism, AOD-9604 has been investigated for cartilage repair and osteoarthritis applications — an entirely different biology from its original lipolysis-focused development. In vitro studies demonstrated that AOD-9604 promotes proteoglycan synthesis in chondrocytes (the cells maintaining articular cartilage) and reduces pro-inflammatory signalling in the joint environment. In vivo animal osteoarthritis models showed reduced cartilage degradation in AOD-9604-treated animals.

This articular cartilage biology was the basis for clinical investigation by Paradigm Biopharmaceuticals, who licensed AOD-9604 for intra-articular injection in osteoarthritis (as Zilosul). Phase 2 and Phase 3 trials in knee osteoarthritis have been conducted. This unexpected application demonstrates the importance of broad mechanistic investigation of research peptides — the lipolytic and cartilage-protective activities of AOD-9604 appear to reflect different binding targets, but both are biologically real.

Research Applications in Adipose Biology

For researchers specifically studying adipose tissue biology, AOD-9604 provides several experimental advantages over full-length GH as a lipolysis research tool:

It produces clean lipolysis without insulin resistance confound — allowing fat mobilisation to be studied in isolation from the metabolic complications of GHR activation. This makes it useful for studies of triglyceride mobilisation, adipocyte biology, and fat oxidation where insulin resistance would alter the experimental model.

It provides a GH-independent reference compound for dissecting which fat metabolism effects are GHR-mediated (blocked by AOD-9604) versus GH-fragment mediated (activated by AOD-9604) — useful for mechanistic attribution studies of GH biology.

Summary

AOD-9604’s design as a GH-fragment selective for lipolytic over growth-promoting effects makes it a scientifically motivated research tool for adipose biology — providing GH-like fat mobilisation without GHR-mediated IGF-1, insulin resistance, or growth effects. Its clinical development history, GRAS status, and subsequent cartilage application discovery give it an unusually rich regulatory and pharmacological profile for a research peptide. For UK researchers working in adipose biology, obesity pharmacology, fat metabolism mechanisms, or articular cartilage biology, AOD-9604 offers a selective, clinically-validated research tool with documented safety and a well-characterised pharmacological profile.